| Literature DB >> 30713334 |
Beibei Zhu1, Yanyan Wang1, Xuan Zhou1, Chunyan Cao1, Yan Zong1, Xiaodan Zhao1, Zuohong Sha1, Xiaoyun Zhao1, Shanhang Han2.
Abstract
BACKGROUND Dermatology patients continue to receive improved treatment, but for patients with psoriasis, there have been few studies on ways to improve patient management by improving communication with patients and their dermatologists. This study aimed to investigate the feasibility and efficacy of cloud-based interactive patient and physician management of psoriasis. MATERIAL AND METHODS The cloud-based platform was created by professional software engineers to educate and manage patients with psoriasis in a single hospital, where patients and research staff had a network platform for sharing data. A total of 79 patients with psoriasis were included in this study and were randomly divided into the control group (n=39) and the intervention group (n=40). Patients in the control group were given a psoriasis nursing manual and underwent regular follow-up. Patients in the intervention group were managed using the cloud platform, with the same management as the control group. The Psoriasis Area Severity Index (PASI), the Self-Rating Anxiety Scale (SAS), the Dermatology Life Quality Index (DLQI), and the Symptom Checklist-90-Revised (SCL-90-R) were used. RESULTS Cloud-based interactive patient and physician management resulted in clinical improvement, and reduced the degree of anxiety in patients with psoriasis and improved their physical and mental health. Patients in the intervention group had an improved understanding of psoriasis treatment, resulting in an improved relationship with the medical staff and improved treatment compliance. CONCLUSIONS Cloud-based interactive patient and physician management improved the mental health and quality of life for patients with psoriasis and allowed patients to manage their disease more effectively.Entities:
Mesh:
Year: 2019 PMID: 30713334 PMCID: PMC6371740 DOI: 10.12659/MSM.913304
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Workflow process of cloud-based patient and physician medical interactive management in psoriasis.
Comparison of the demographic and clinical information of individuals between the two groups.
| Group | n | Gender | Age (yrs) | Course of disease | Current therapies | |||
|---|---|---|---|---|---|---|---|---|
| Male | Female | None | Emollients only | Active therapies | ||||
| Control group | 39 | 22 | 17 | 44.3±18.6 | 11.70±12.76 | 2 | 9 | 28 |
| Intervention group | 40 | 24 | 16 | 43.5±17.3 | 10.99±11.48 | 3 | 8 | 29 |
| P-value | >0.05 | >0.05 | >0.05 | >0.05 | ||||
Comparison of the Psoriasis Area Severity Index (PASI), the Self-Rating Anxiety Scale (SAS), and the Dermatology Life Quality Index (DLQI) scores at baseline and the end of follow-up between the two study groups.
| Group | n | PASI | SAS | DLQI | |||
|---|---|---|---|---|---|---|---|
| Baseline | End of follow-up | Baseline | End of follow-up | Baseline | End of follow-up | ||
| Control group | 39 | 25.64±10.83 | 25.01±11.77 | 11.97±6.21 | 10.99±5.78 | 43.77±6.81 | 42.88±5.96 |
| Intervention group | 40 | 24.92±9.86 | 10.38±5.76 | 12.43±4.74 | 4.53±3.44 | 42.83±5.97 | 25.03±4.34 |
| P-value | >0.05 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 | |
PASI – Psoriasis Area and Severity Index; SAS – Self-Rating Anxiety Scale; DLQI – Dermatology Life Quality Index.
Comparison of the results of a questionnaire on knowledge of psoriasis at the end of follow-up between the two study groups.
| Question | Control group | Intervention group | ||||
|---|---|---|---|---|---|---|
| Right | Wrong | Accuracy (%) | Right | Wrong | Accuracy (%) | |
| Whether psoriasis is contagious or not? | 37 | 2 | 94.9 | 40 | 0 | 100 |
| Whether psoriasis is hereditary or not? | 26 | 13 | 66.7 | 39 | 1 | 97.5 |
| Do patients with psoriasis need to avoid certain food? | 8 | 31 | 20.5 | 38 | 2 | 95.0 |
| Can the psoriasis be cured? | 34 | 5 | 87.2 | 40 | 0 | 100 |
| Whether traditional Chinese medicines are safe and nontoxic or not? | 16 | 23 | 41.0 | 40 | 0 | 100 |
| Whether mental and emotional factors affect the disease or not? | 38 | 1 | 97.4 | 40 | 0 | 100 |
| Only drugs can treat psoriasis? | 19 | 20 | 48.7 | 40 | 0 | 100 |
| Do you believe in folk prescription or advertisement? | 23 | 16 | 59.0 | 39 | 1 | 97.5 |
| Are you aware of the hazards of anti-cancer drugs, hormones, immunosuppressive agents and heavy metal preparations? | 17 | 22 | 43.6 | 39 | 1 | 97.5 |
| Are there effective measures to prevent recurrence or exacerbation of psoriasis? | 32 | 7 | 82.1 | 40 | 0 | 100 |
| Are you eager to pursue the immediate effect? | 5 | 34 | 12.8 | 39 | 1 | 97.5 |
Comparison of the results of the Symptom Checklist-90-Revised (SCL-90-R) questionnaire survey at the end of follow-up between the two groups.
| Control group | Intervention group | P-value | |
|---|---|---|---|
| SOM | 16.09±4.43 | 9.22±3.22 | <0.05 |
| O-C | 13.86±3.01 | 11.43±5.57 | 0.264 |
| I-S | 14.55±4.21 | 10.27±3.39 | 0.422 |
| DEP | 27.50±5.44 | 21.53±4.42 | <0.05 |
| ANX | 24.37±4.29 | 15.28±3.27 | <0.05 |
| HOS | 12.69±3.66 | 7.28±3.37 | <0.05 |
| PHOB | 10.20±3.28 | 8.16±2.18 | 0.185 |
| PAR | 12.35±4.50 | 9.34±3.23 | 0.521 |
| PSY | 14.26±4.35 | 9.26±4.33 | <0.05 |
SOM – somatization; O-C – obsessive-compulsive behavior; I-S – interpersonal sensitivity; DEP – depression; ANX – anxiety; HOS – hostility; PHOB – phobic anxiety; PAR – paranoid ideation; PSY – psychoticism.